Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
3 investors
Altos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.
3 investors
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease. Its programs are in preclinical through Phase II development.
3 investors
3 investors
AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease. The company focuses on addressing the unmet need of adult-onset HPP patients who lack disease-specific treatment options.
3 investors
AmacaThera is a biotech company developing a tunable injectable hydrogel drug-delivery platform, based on hyaluronic acid and methylcellulose, for localized and long-acting release of therapeutics such as small molecules, biologics, peptides, and cells. It partners with pharmaceutical companies to co-develop products across applications including post-surgical non-opioid pain management and oncology.
3 investors
Amaroq Therapeutics develops first-in-class therapies targeting long non-coding RNAs (lncRNAs) implicated in oncology and other diseases. The company uses proprietary platforms to discover, validate, and create precision medicines against disease-relevant lncRNAs, focusing initially on oncology programs with high unmet medical need.
3 investors
Amber Bio is a biotechnology company developing a novel RNA writing platform capable of multi-kilobase gene edits that can treat multiple mutations across patients with a single product.
3 investors
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins. The company designs degraders that combine favorable properties of PROTAC and molecular glue approaches to address a wider range of tissues and disease indications.
3 investors
AMPLY Discovery is a UK-based biotech company that uses AI and computational biology to identify therapeutic targets in non-coding regions of the genome and develop first-in-class drugs through an integrated discovery platform combining machine learning with wet-lab validation. The company is developing therapeutics for oncology and drug-resistant infectious diseases, particularly antimicrobial-peptide and long non-coding RNA oligonucleotide programmes.
3 investors
Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and other serious diseases.
3 investors
Angle was a cryptocurrency protocol that issued stablecoin tokens (USDA and EURA) that could be redeemed 1:1. The protocol is shutting down with a redemption deadline of March 1, 2027.
3 investors
Ångström AI develops AI-powered physics simulations for pharmaceutical drug discovery, computing molecular properties like solubility, lipophilicity, and crystal structure stability to replace traditional lab experiments. The platform uses machine learning interatomic potentials and free energy calculations to accelerate and derisk solid form development for pharma companies.
3 investors
Anja Health provides cord blood banking and stem cell storage services from umbilical cords and placentas for families. The company aims to make stem cell preservation accessible and affordable for new parents.
3 investors
Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its therapies aim to block complement-driven damage affecting the body, brain, and eye.
3 investors
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.
3 investors
Anthology develops designer and hybrid genomes by decoding genomic "language" to engineer microbes that convert feedstocks such as sugars, plastics, and agricultural waste into products like chemicals, materials, and food ingredients. Its applications include producing functional proteins for healthy aging and GLP-1 companion foods, enzymes to improve animal health, and carbon-neutral bioproduction for a circular bioeconomy.
3 investors
Apollo Therapeutics is a portfolio biopharmaceutical company that translates academic biology and medical research into new medicines, operating over 20 therapeutic programs including six in clinical development. It runs an R&D platform partnered with leading universities and research institutes, and also in-licenses or acquires clinical-stage programs, with operations in Cambridge and Oxford, UK, and Boston and Chicago, USA.</parameter> <parameter name="founders">[]
3 investors
Apollomics is a biotechnology company focused on discovering and developing oncology therapies designed to combine with other treatments, using approaches that engage the immune system and target specific molecular pathways to inhibit cancer. It operates as a publicly traded (Nasdaq-listed) drug developer with clinical programs including vebreltinib (APL-101).
3 investors
Aptimmune develops vaccines for swine health, partnering with vaccine development and swine health consulting companies to speed product development, testing and manufacturing. It serves the swine veterinary and animal health industry.
3 investors
Aqemia is a drug discovery company that uses generative AI and quantum-inspired physics to design new small-molecule medicines and advance its own drug discovery pipeline. It applies these science engines to accelerate the identification of drug candidates in the pharmaceutical and biotech sector.
3 investors
Arda develops therapeutics using single-cell computational biology to target and eliminate pathogenic cells in chronic diseases. The company combines drug development expertise with cellular biology to create new therapeutic approaches.
3 investors
Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs. It focuses on therapeutic areas including chronic kidney disease with hyperphosphatemia and irritable bowel syndrome with constipation.
3 investors
Arecor develops proprietary therapeutics for diabetes and other cardiometabolic diseases using its Arestat formulation and drug delivery technology platform. It also partners with pharmaceutical and medtech companies to improve therapeutic profiles.
3 investors